Neonatal Care Transparency Act of 2025

Senate Bill

S. 2433

119th Congress

Neonatal Care Transparency Act of 2025

In Committee

Introduced:Jul 24, 2025

Primary Sponsor

Kevin Cramer

Senator

Republican

ND

Cosponsors

0

Quick Stats

Policy Area

Health

Summary

The Neonatal Care Transparency Act of 2025 would reauthorize several programs and activities related to mental health and substance use disorder services through 2028. This includes enabling access to overdose reversal drugs, supporting the detection of synthetic opioids, and providing training and workforce development for mental health and substance use disorder providers.

Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

SponsorKevin Cramer (R-ND)

Introduced7/24/2025

StatusRead twice and referred to the Committee on Health, Education, Labor, and Pensions.

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

Neonatal Care Transparency Act of 2025

The Neonatal Care Transparency Act of 2025 would reauthorize several programs and activities related to mental health and substance use disorder services through 2028. This includes enabling access to overdose reversal drugs, supporting the detection of synthe

Community Breakdown

Pass

0%

Fail

0%

0 predictions

The Neonatal Care Transparency Act of 2025 would reauthorize several programs and activities related to mental health and substance use disorder services through 2028. This includes enabling access to overdose reversal drugs, supporting the detection of synthetic opioids, and providing training and workforce development for mental health and substance use disorder providers.

Bill Number: 2433
Sponsor: Kevin Cramer (R-ND)
Introduced: 7/24/2025
Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: Neonatal Care Transparency Act of 2025
Bill Number: 2433
Sponsor: Kevin Cramer (R-ND)
Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced: 7/24/2025
Summary: The Neonatal Care Transparency Act of 2025 would reauthorize several programs and activities related to mental health and substance use disorder services through 2028. This includes enabling access to overdose reversal drugs, supporting the detection of synthetic opioids, and providing training and

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

The Neonatal Care Transparency Act of 2025 would reauthorize several programs and activities related to mental health and substance use disorder services through 2028. This includes enabling access to overdose reversal drugs, supporting the detection of synthetic opioids, and providing training and workforce development for mental health and substance use disorder providers.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

SUPPORT for Patients and Communities Reauthorization Act of 2023This bill reauthorizes through FY2028 programs and activities relating to mental health and substance use disorder services.Reauthorized programs and activities include <ul><li>programs that enable access to drugs or devices that temporarily reverse opioid overdoses,</li><li>activities to support the capacity of laboratories to detect synthetic opioids (e.g., fentanyl),</li><li>residential treatment programs for pregnant and postpartum individuals, and</li><li>training and workforce development for providers of mental health and substance use disorder services.</li></ul>The bill also modifies certain requirements relating to the regulation of controlled substances and the provision of mental health and substance use disorder services, including by requiring (1) the issuance of federal guidance to support at-home safe disposal systems for drugs, (2) studies to evaluate the efficacy of opioid treatment through buprenorphine and methadone, and (3) evaluations of the use of certain block grants by states to treat individuals with serious mental illnesses.

Key Points

Main provisions of the bill

Reauthorizes programs that enable access to drugs or devices that temporarily reverse opioid overdoses
Supports activities to build the capacity of laboratories to detect synthetic opioids like fentanyl
Reauthorizes residential treatment programs for pregnant and postpartum individuals with substance use disorders
Requires federal guidance to support at-home safe disposal systems for drugs
Mandates studies to evaluate the efficacy of opioid treatment using buprenorphine and methadone

How This Impacts Americans

Potential effects on citizens and communities

If passed, this bill would primarily impact individuals struggling with mental health and substance use disorders, as well as their families and communities. It would help improve access to addiction treatment and overdose prevention services, especially for vulnerable populations like pregnant and postpartum women. Healthcare providers and labs would also be affected through increased training, workforce development, and enhanced opioid detection capabilities.

Policy Areas

Primary Policy Area

Health

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

2433, 119th Congress (2025). "Neonatal Care Transparency Act of 2025". Source: Voter's Right Platform. https://votersright.org/bills/118-s-2433

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.